Inovio pharmaceuticals stock.

ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses.Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?See Inovio Pharmaceuticals, Inc. (INO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?As of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.

Inovio Falls on Wider Loss; Progress Shown in COVID Vaccine Trial. Inovio shares eased after the drugmaker reported a wider loss. Earlier it had reported ...Inovio Pharmaceuticals is a small-ish biotech company with a market cap of around $519 million. The company ended 2022's second quarter with $348 million in cash and short-term investments, which ...The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ...

Aug 9, 2023 · Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the promise of DNA medicines for ...

Inovio Pharmaceuticals (INO-5.34%) has given different groups of investors some wildly varying stock performances this year. If you bought its shares at the beginning of 2020, your investment is ...Inovio Pharmaceuticals. Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate ... Inovio Pharmaceuticals (INO) Company Description: Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA ...Find the latest Inovio Pharmaceuticals, Inc. (INO.MX) stock quote, history, news and other vital information to help you with your stock trading and investing.WebAs of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.

View Inovio Pharmaceuticals, Inc INO investment & stock information. Get the latest Inovio Pharmaceuticals, Inc INO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

The Action asserts claims on behalf of all Persons who purchased or otherwise acquired the common stock of Inovio between February 14, 2020 and August 10, 2020, inclusive. Plaintiffs' claims in the Action are set forth in the Second Amended Consolidated Class Action Complaint for Violation of the Federal Securities Laws filed on February 17 ...

Nov. 01. MT. Maxim Lowers Price Target for Inovio Pharmaceuticals to $5 From $11, Maintains Buy Rating. 2022. MT. RBC Reinstates Inovio Pharmaceuticals at Sector Perform-Speculative Risk, Assigns $4 Price Target, Awaiting 'More Attractive' Entry Point, 'Clearer Path for Value Creation'.INO | Complete Inovio Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective ...See why we are neutral on INO stock. Inovio faces an uphill battle in turning around its performance as it closes out its first full ... 2023 7:15 AM ET Inovio Pharmaceuticals, Inc. (INO) 11 ...Get Inovio Pharmaceuticals Inc (INO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsInovio Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 5 hold ratings, and 1 sell ratings. What was the 52-week low for ...U.S.: Nasdaq. Add to Watchlist. INO. About Inovio Pharmaceuticals Inc. Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious ...

Background Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting …WebInovio Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 5 hold ratings, and 1 sell ratings. What was the 52-week low for ... Inovio Pharmaceuticals saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 24,940,000 shares, a decline of 3.0% from the previous total of 25,710,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are ...WebFrom 1998 through today, Inovio Pharmaceuticals' stock history has been largely a depressing one. A quick analysis of Inovio Pharmaceuticals ' ( INO 2.77%) stock performance history shows plenty ...According to the issued ratings of 1 analysts in the last year, the consensus rating for Inovio Pharmaceuticals stock is Hold based on the current 1 hold rating for INO. The average twelve-month price prediction for Inovio Pharmaceuticals is $2.00 with a high price target of $2.00 and a low price target of $2.00.The year-over-year increase in G&A expenses was primarily due to a $14.0 million non-cash expense related to the settlement of INOVIO's securities class action litigation, including the issuance of INOVIO common stock as part of the settlement, $14.3 million in higher legal expenses, primarily related to litigation matters, $6.9 million in one ...

Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.INO is the ticker symbol for Inovio Pharmaceuticals, Inc., a biotechnology company that develops and commercializes DNA medicines to treat and protect people from HPV-associated diseases, cancer, and infectious diseases. The web page shows its stock price, news, analysis, and performance outlook on NasdaqGS.

Nov 30, 2023 · Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA ... Nov 30, 2023 · Inovio Pharmaceuticals Stock Forecast. ... According to 1 stock analyst, the 12-month stock price forecast for INO stock stock is $2.00, which predicts an increase of ... Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 0.40, with a high estimate of 0.40 and a low estimate of 0.40. The ...17,042.88 +49.44(+0.29%) CRUDE OIL 76.00 -1.86(-2.39%) GOLD FUTURES 2,055.10 -12.00(-0.58%) DOW 35,763.06 +332.64(+0.94%) Bitcoin GBP 29,890.83 -117.13( …Stock split history for Inovio Pharmaceuticals since 1998. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.17,042.88 +49.44(+0.29%) CRUDE OIL 76.00 -1.86(-2.39%) GOLD FUTURES 2,055.10 -12.00(-0.58%) DOW 35,763.06 +332.64(+0.94%) Bitcoin GBP 29,890.83 -117.13( …

Nov 30, 2023 · Inovio Pharmaceuticals Stock Forecast. ... According to 1 stock analyst, the 12-month stock price forecast for INO stock stock is $2.00, which predicts an increase of ...

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. About the company. INO fundamental analysis.

The stock option has an exercise price of $0.36, the closing price of INOVIO's common stock on the Grant Date. The stock option will vest and become exercisable with respect to one-fourth of the shares underlying the stock option vested on the Grant Date, and an additional one-fourth of the shares underlying the stock option on the first ...Dec 1, 2023 · Stock analysis for Inovio Pharmaceuticals Inc (INO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. INO is the ticker symbol for Inovio Pharmaceuticals, Inc., a biotechnology company that develops and commercializes DNA medicines to treat and protect people from HPV-associated diseases, cancer, and infectious diseases. The web page shows its stock price, news, analysis, and performance outlook on NasdaqGS. Today, let's take a closer look at clinical-stage biotech company Inovio Pharmaceuticals ( INO 4.66%) and see whether it has what it takes to join that select group of millionaire-maker stocks ...Pennsylvania-based Inovio Pharmaceuticals is a biotechnology business with a focus on DNA-based medicine. During the onset of the COVID-19 crisis, some traders bought INO stock as a bet on Inovio ...Inovio Pharmaceuticals stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast INO stock forecast for 2023 – 2027. Last updated: November 21, 2023. Are you interested in Inovio Pharmaceuticals, Inc. stocks prediction?Nov 29, 2023 · 1 Wall Street analysts have issued twelve-month target prices for Inovio Pharmaceuticals' stock. Their INO share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 423.3% from the stock's current price. Green flag: A rich pipeline. Small-cap biotechs need promising pipeline programs to attract attention. In this department, Inovio Pharmaceuticals doesn't disappoint. The company currently boasts ...Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript November 9, 2023 Inovio Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS ...

Shares of Inovio Pharmaceuticals (INO 0.96%) ... There's also the worry the stock could be delisted from the Nasdaq Stock Market if it continues to trade below $1, which would make it more ...Inovio Pharmaceuticals Inc. closed $1.59 below its 52-week high ($1.99), which the company reached on January 13th. The stock outperformed some of its competitors …According to the issued ratings of 1 analysts in the last year, the consensus rating for Inovio Pharmaceuticals stock is Hold based on the current 1 hold rating for INO. The average twelve-month price prediction for Inovio Pharmaceuticals is $2.00 with a high price target of $2.00 and a low price target of $2.00.Complete Inovio Pharmaceuticals Inc. stock information by Barron's. View real-time INO stock price and news, along with industry-best analysis. Instagram:https://instagram. does microsoft stock pay dividendsjim cramer mad money recap yesterdaywhich broker is best for mt5ubi stock Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information Sporting 0.96% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 12/01/23 when the INO stock price touched $0.40 or saw a rise of 6.08%.Find real-time INO - Inovio Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. ... Inovio Pharmaceuticals Inc (NASDAQ:INO) 0.4291. Delayed Data. As of Nov 17 ... math solver googlebest mortgage lenders in houston texas Aug 9, 2023 · Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the promise of DNA medicines for ... kennedy 50 cent value 12 Feb 2014 ... Executives and guests of Inovio Pharmaceuticals, Inc. will visit the New York Stock Exchange (NYSE) on Wednesday, Feb 12, 2014.In a major shakeup at Inovio Pharmaceuticals, company co-founder J. Joseph Kim is out as CEO. ... In early morning trading, Inovio's stock was down more than 31% at $1.72 per share.